Enterprise Therapeutics
PrivateLast Round
Series B
Extension
Jan 30, 2024
Total Funding Raised
$87.1M
Momentum Score
25 /100
Company Overview
Enterprise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for respiratory diseases. The company's primary strategy is to develop treatments that address the underlying mechanisms of mucus congestion in conditions such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and severe asthma. By targeting ion channels like ENaC and TMEM16A, its therapies aim to hydrate and clear mucus, thereby restoring lung function and reducing infections. Founded in 2014, the company is backed by several venture capital firms. In October 2020, its TMEM16A potentiator portfolio was acquired by Roche, but the company continued operations. Enterprise Therapeutics secured a £26 million Series B follow-on financing in January 2024 to advance its lead program, ETD001, into a Phase 2a clinical trial for cystic fibrosis.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enterprise Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Enterprise Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jan 30, 2024 | ||||
| M&A | Oct 7, 2020 | ||||
| Grant | Oct 15, 2019 | ||||
| Series B | Apr 12, 2018 | ||||
| Grant | Apr 5, 2017 | ||||
VC Round | Nov 10, 2016 |
Key People
Founding team and executive leadership
Enterprise Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IP Group | Series B Extension, Series B |
| Epidarex Capital | Series B Extension, Series B, Series A, VC Round |
| Cystic Fibrosis Trust | Grant |
| Versant Ventures | Series B Extension, Series B |
| Imperial Innovations | Series A, VC Round |
| Cystic Fibrosis Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Monthly visitors increased 37% MoM, reaching 1.2K.
Enterprise Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Enterprise Therapeutics's valuation, stock price, and market status.
